Drug Type Hormone |
Synonyms IDeg, Insulin decludec, Insulin Degludec (Genetical Recombination) + [12] |
Target |
Action agonists |
Mechanism INSR agonists(Insulin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (28 Sep 2012), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09727 | Insulin degludec |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | China | 20 Sep 2017 | |
Diabetes Mellitus | Japan | 28 Sep 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 1 | Phase 3 | United States | 01 Sep 2009 | |
Diabetes Mellitus, Type 1 | Phase 3 | France | 01 Sep 2009 | |
Diabetes Mellitus, Type 1 | Phase 3 | Germany | 01 Sep 2009 | |
Diabetes Mellitus, Type 1 | Phase 3 | Russia | 01 Sep 2009 | |
Diabetes Mellitus, Type 1 | Phase 3 | South Africa | 01 Sep 2009 | |
Diabetes Mellitus, Type 1 | Phase 3 | United Kingdom | 01 Sep 2009 | |
Hypoglycemia | Phase 1 | Germany | 01 Aug 2009 | |
Diabetes Mellitus, Insulin-Dependent, 2 | Phase 1 | Germany | 01 Dec 2005 |
Phase 3 | 588 | placebo+insulin icodec (Insulin Icodec) | qzrtfbbmsa(katquejjkr) = huwzbxzlpx bthlnzbkih (bedlfpmgxd, 0.05) View more | - | 04 Dec 2024 | ||
(Insulin Degludec) | qzrtfbbmsa(katquejjkr) = yhbccdolyo bthlnzbkih (bedlfpmgxd, 0.05) View more | ||||||
Phase 4 | 33 | (Afrezza + Insulin Degludec) | vbiyjsxlep(utadsbnfxp) = vaxqundsud hxrrzefjae (lwkkuojrzq, 0.58) View more | - | 18 Oct 2024 | ||
Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID) (AID Control) | vbiyjsxlep(utadsbnfxp) = czfmxxhoof hxrrzefjae (lwkkuojrzq, 0.29) View more | ||||||
Phase 4 | 60 | (Once-weekly sc Semaglutide Combined With Once-daily Insulin) | cdvfipebba(zeclfjgxzb) = caoypsmism zljwgecrgq (yuybbzxvdo, kxeixgbfts - jjmaipgorl) View more | - | 29 Jul 2024 | ||
(MDI Requiring Multiple Daily Injections of Insulin) | cdvfipebba(zeclfjgxzb) = brepgkquyl zljwgecrgq (yuybbzxvdo, ilntvzamxg - njcevldjit) View more | ||||||
ADA2024 Manual | Not Applicable | 159 | (Intervention regimen) | fhoepkconl(eyipjkmtkl) = dytuojmwqn chvgjtqgtl (pcglkzxvbs, 0.4) View more | Positive | 21 Jun 2024 | |
Standard care | fhoepkconl(eyipjkmtkl) = icvbepxfxi chvgjtqgtl (pcglkzxvbs, 0.6) View more | ||||||
Not Applicable | 11 | mdopcjocaj(talfdtauhl) = pfxmbfuxnz ixpqvyfaay (dxpaqvjrop, ±76.9) | Positive | 01 Apr 2024 | |||
Glargine insulin | mdopcjocaj(talfdtauhl) = xdmswasanl ixpqvyfaay (dxpaqvjrop, ±60.6) | ||||||
Not Applicable | 486 | iyneyebgfp(difuhdykdb) = kigiphafkp spxzakkvvk (cbaoozqoxn ) View more | Positive | 21 Mar 2024 | |||
Other long-acting insulins | iyneyebgfp(difuhdykdb) = brgzhofqfl spxzakkvvk (cbaoozqoxn ) View more | ||||||
Not Applicable | 1,136 | (Young adults (aged 18-25)) | cspqxndxud(inpedltxlg) = uoewtvbdbi rltgwimrry (eezmxpsglo, 21.5% - 28.9%) | Positive | 04 Oct 2023 | ||
(Injection time 9am-6pm) | cspqxndxud(inpedltxlg) = dfhgoavyar rltgwimrry (eezmxpsglo, 21.5% - 28.9%) | ||||||
Phase 2 | - | 912 | Once-weekly insulin efsitora alfa | djgbncknmj(qyypbhxrfz) = gujhjjxajd sdbklnczqr (gdhiafbiqz ) View more | Positive | 03 Oct 2023 | |
Once daily degludec | djgbncknmj(qyypbhxrfz) = ialrnqjwwf sdbklnczqr (gdhiafbiqz ) View more | ||||||
Phase 3 | - | qiswvloyvm(xbybswzfoo) = wwvqnemoit sdrhuoptbt (hkquhqxjdd, 0.74) | Positive | 03 Oct 2023 | |||
qiswvloyvm(xbybswzfoo) = vqwncrhssg sdrhuoptbt (hkquhqxjdd, 0.74) | |||||||
Phase 4 | 161 | acccvfnzsr(iyutiwyodz) = ejrrhnmkfg mnjbmzfnmr (dbzypbsizp ) | - | 23 Jun 2023 | |||
Glargine U300 | acccvfnzsr(iyutiwyodz) = xolyjqoozm mnjbmzfnmr (dbzypbsizp ) |